Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
milk fat globule epidermal growth factor 8
- Development stage
- Preclinical
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous, Intraperitoneal
01
Overview
Milk fat globule epidermal growth factor 8 is a recombinant protein biologic based on the endogenous secreted glycoprotein MFG-E8, also known as lactadherin. It is being investigated primarily in preclinical and translational research as an anti-inflammatory and tissue-protective therapeutic for acute injury and inflammatory disorders, including hemorrhagic shock, acute lung injury, intestinal ischemia-reperfusion injury, spinal cord injury, neonatal sepsis, renal injury, and intestinal fibrosis. Mechanistically, MFG-E8 binds phosphatidylserine on apoptotic cells and engages integrins such as alpha v beta 3 and alpha v beta 5 through its RGD motif, thereby promoting efferocytosis, dampening inflammatory signaling, and supporting resolution of tissue injury. Available information indicates academic and experimental development rather than a clearly identified commercial drug product or branded pharmaceutical program.
- Other names
- milk fat globule epidermal growth factor 8MFG-E8MFG-E-8MFG-E 8MFGE8MFGE-8MFGE 8lactadherin
02
Targets
αVβ3 (Integrin αVβ3)αVβ5 (Integrin αVβ5)PS (Phosphatidylserine)
Beyond the preview
Go deeper on milk fat globule epidermal growth factor 8.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on milk fat globule epidermal growth factor 8.